bio-america-2016_keynote

6 / 7

Volume 6, Issue 8 (Suppl) J Biotechnol Biomater
ISSN: 2155-952X JBTBM, an open access journal Bio America 2016
November 28-30, 2016
Page 36
Notes:
conferenceseries.com
November 28-30, 2016 San Francisco, USA
13th Biotechnology Congress
A novel strategy for developing long acting recombinant proteins: From bench to bedside
One major issue regarding the clinical use of many peptides is their short half-life due to the rapid clearance from the
circulation. To overcome this problem, we succeeded to ligate the signal sequence of O-linked oligosaccharides to the
coding sequence of the hormones. The cassette gene that has been used contains the sequence of the carboxyl-terminal
peptide (CTP) of human chorionic gonadotropin β (hCGβ) subunit. The CTP contains 28 amino acids with four O-linked
oligosaccharide recognition sites. It was postulated that O-linked oligosaccharides add flexibility, hydrophilicity and stability to
the protein. On the other hand, it was suggested that the four O-linked oligosaccharides play an important role in preventing
plasma clearance and thus increasing the half-life of the protein in circulation. Using this strategy, we succeeded to ligate the
CTP to the coding sequence of follitropin (FSH), thyrotropin (TSH), erythropoietin (EPO) growth hormone (GH) and thus to
increase the longevity and bioactivity of these proteins in vivo. Interestingly, the new analogs of FSH and GH were found non-
immunogenic in human and it is already passed successfully clinical trials phase III and phase II respectively. Moreover, FSH
long acting was approved by the European Commission (EC) for treatment of fertility. In addition, our results indicated that
long acting GH is not toxic in monkeys and the results from clinical trials phase I and phase II seem to be promising. Designing
long acting peptides will diminish the cost of these drugs and perhaps reduce the number of injections in the clinical protocols.
Biography
Fuad Fares has completed his MSc and DSc studies at the Faculty of Medicine, Technion-Israel Institute of Technology and Postdoctoral studies at the Department
of Molecular Biology and Pharmacology, School of Medicine, Washington University, St. Louis Missouri, USA. He has developed the Molecular Genetic Laboratory
at Carmel Medical Center, Haifa, Israel and led the laboratory for last 20 years until 2015. He is the Head of Molecular Genetic Laboratory at the Department of
Human Biology, University of Haifa, Israel since 2004 and teaching genetics, genetic engineering and endocrinology at the Faculty of Natural Sciences at University
of Haifa, Israel. He has published more than 90 manuscripts in reputed journals and serving as a Member of the Israel Council for Higher Education since 15 years.
Moreover, he is the Founder and the Inventor of PROLOR Biotech Company for designing long-acting recombinant proteins.
Fuad Fares
University of Haifa, Israel
Fuad Fares, J Biotechnol Biomater 2016, 6:8(Suppl)